Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients

NCT ID: NCT01786161

Last Updated: 2017-06-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-09-30
• Study Completion Date: 2016-06-30

Brief Summary

Vancomycin is an essential antimicrobial which is frequently used in the ICU for suspected methicillin-resistant Staphylococcus aureus (MRSA) infection. Therefore, it is vital to optimize the dosing of vancomycin for this critically ill population. The most efficacious method of administering vancomycin is debated in the literature. Since vancomycin is associated with slow bactericidal activity, it is important to closely monitor serum concentrations so as to achieve early target serum concentration, particularly when treating aggressive S. aureus infections. One study has shown that vancomycin infused continuously may enable faster and more consistent achievement of a therapeutic serum concentration when compared to intermittent infusion. A faster achievement in the goal serum vancomycin concentration would be a protective factor for intensive care unit mortality in patients with MRSA infection.

Currently in the surgical ICU (SICU) of our institute, vancomycin is administered based on a vancomycin dosing nomogram. Less than fifty percent of the ICU patients following this nomogram achieved target vancomycin concentration of 15 after 24 hours. To better achieve target vancomycin concentration in 24 hours, we developed a new vancomycin dosing nomogram with a continuous infusion. The aim is to determine which of the two dosing nomogram is more efficient and safer for SICU patients.

Detailed Description

Early administration of effective antibiotics is the cornerstone of management in septic patients; however, altered pharmacokinetics in critically ill patients has lead to subtherapeutic antibiotic exposure with standard antibiotic dosing and administration. This is further evidenced by low therapeutic target achievement with our intermittent vancomycin dosing nomogram. Administering vancomycin by continuous infusions may lead to achieving a therapeutic concentration and AUC24 more quickly than the administration by intermittent infusions as well as provide a more consistent concentration throughout the dosing period. Therefore, a new vancomycin continuous infusion nomogram was developed to increase the achievement of a goal vancomycin concentration within 24 hours.

We hypothesized that vancomycin administered as continuous infusion would achieve the therapeutic target sooner and more consistently than when administered as an intermittent infusion in critically ill surgical patients. The aims of this study were to determine the dosing differences between continuous (CIV) and intermittent (IIV) dosing in critically ill surgical intensive care unit (SICU) patients with preserved renal function and whether calculated Cockcroft-Gault Creatinine Clearance (CG CrCL) or measured creatinine clearance (CrCL) is a better predictor of vancomycin clearance.

Conditions

MRSA - Methicillin Resistant Staphylococcus Aureus Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vancomycin with continuous infusion

24 hours continuous infusion

Group Type: EXPERIMENTAL

Vancomycin continuous infusion

Intervention Type: DRUG

Vancomycin 24 hour intravenous continuous infusion

Vancomycin with intermittent dose interval

infusion rate 1000mg/hr

Group Type: ACTIVE_COMPARATOR

Vancomycin intermittent dosing interval

Intervention Type: DRUG

Vancomycin intravenous infusion at rate 1000mg/hr

Interventions

Vancomycin continuous infusion

Vancomycin 24 hour intravenous continuous infusion

Intervention Type: DRUG

Vancomycin intermittent dosing interval

Vancomycin intravenous infusion at rate 1000mg/hr

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male and non-pregnant female > 18 years of age admitted to Surgical ICUs with suspected infection
• Calculated creatinine clearance > 60ml/min

Exclusion Criteria

• Age < 18 years
• Allergic to vancomycin
• Calculated creatinine clearance < 60ml/min
• Pregnant
• Vancomycin administration more than 8 hour and less than 24 hour prior to study enrollment
• Anticipated vancomycin treatment less than 2 days for surgical prophylaxis

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Massachusetts General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Hsin Jung Lin

PharmD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hsin Lin, PharmD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

MGH

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

P 002617

Identifier Type: -

Identifier Source: org_study_id